Biotechnology

Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that it is advancing the clinical development of...

2023-02-01 15:00 3600

CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer

SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche L...

2023-01-31 21:50 3123

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment inAustralia, the United States, and Italy * Presented compelling bioMUSE data at two prestigious industry conferences * Granted a 20-year patent for 100 new compounds targeting Parkinson's...

2023-01-31 20:25 3066

Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic

HONG KONG, Jan. 31, 2023 /PRNewswire/ -- In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donateRMB10...

2023-01-31 16:10 3432

Singleron to present single cell sequencing solutions at the 36th Molecular Biology of Plants Conference

COLOGNE, Germany, Jan. 31, 2023 /PRNewswire/ -- Singleron Biotechnologies , a leader in single cell sequencing, will present at the upcoming 36th Molecular Biology of Plants 2023 (MBP2023) Conference of the Section Plant Physiology and Molecular Biology of the German Socie...

2023-01-31 16:00 2129

Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region

* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a double-digit royalties on Net Sales * CS Pharmaceuticals will receive exclusive rights for development and commercialization of Bersiporocin for the treatment of IPF and other respiratory indica...

2023-01-31 14:43 3715

Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology

SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autolog...

2023-01-31 09:24 1893

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China

HANGZHOU, China and SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of patient dosing in Phase 3 clinical tr...

2023-01-31 08:00 2506

Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC

With a proven biotech market leadership position, Novotech's compelling value proposition drives its sustained success in delivering biotech clinical trials. SAN ANTONIO, Jan. 31, 2023 /PRNewswire/ -- Frost & Sullivan recently analyzed theAsia-Pacific contract research organization industry and, ...

2023-01-31 05:37 2178

Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China

BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in p...

2023-01-30 23:00 2246

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

* ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. * ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. * ORSERDU is the first endocrine innovation in more than 20 years, specif...

2023-01-30 20:39 2503

Duoning Headquarters in Fengxian Biotechnology Park with Centers for R&D and Technology Applications

SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Shanghai Duoning Biotechnology Co., Ltd. ("Duoning") announced that the company signed an Agreement on theTransfer of the Right to Use State-owned Construction Land with the Bureau of Planning and Natural Resources of Fengxian District,Shanghai and official...

2023-01-30 18:00 2845

MGI Makes its Mark in Dubai with Latest Platforms at MEDLAB Middle East and Arab Health

DUBAI, UAE, Jan. 30, 2023 /PRNewswire/ --  MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, will introduce many of its latest gene sequencing platforms and sample preparation system at MEDLAB Middle East 2023, ...

2023-01-30 16:00 2227

Kalbe Consumer Health Crowned Winner at the Asia Pacific Enterprise Awards 2022 Regional Edition

SINGAPORE, Jan. 27, 2023 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...

2023-01-30 11:26 2629

Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)

SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib(ABSK021)has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients...

2023-01-30 11:00 3398

Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases

SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially ...

2023-01-30 10:00 2173

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

* SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in theKingdom of Saudi Arabia(KSA) * SK bioscience also explained a new global partnership model aiming to promote public health in deve...

2023-01-27 20:00 4069

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results

* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...

2023-01-27 14:52 3652

DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease

SALT LAKE CITY, Jan. 27, 2023 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the U.S. Food and Drug ...

2023-01-27 08:46 3166

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA

--Preclinical studies show that ASC10-A, the active metabolite of double prodrug ASC10, has potent antiviral activities against both monkeypox and SARS-CoV-2 viruses --Ascletis has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent applicati...

2023-01-26 21:08 3305
1 ... 127128129130131132133 ... 307